The Authors Reply:  by Bomback, Andrew S. et al.
Sugar-sweetened soda
consumption, hyperuricemia,
and kidney disease
To the Editor: We read with interest the article by Bomback
et al.1 reporting increased frequency of hyperuricemia and
chronic kidney disease (CKD) among persons with increased
sugar-sweetened soda consumption.
However, we wish to note a number of methodological
shortcomings. First, the authors did not consider the
medications that can alter serum uric acid (UA) level,
including low-dose aspirin, angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, fenoﬁbrate, and
thiazide diuretics.2 We also do not know about some
concomitant medical disorders that may cause elevated UA
level, such as pseuriasis, multiple sclerosis, Parkinson’s, and
cardiovascular disease.3
Second, we do not know how many of these hyperuricemic
patients developed gout disease and received allopurinol or
other uricosuric drugs. Third, the authors reported only
laboratory creatinine value as evidence of UA-associated CKD.
However, during such a long observation period, many of these
patients may have had alternative reasons for their reduced
glomerular ﬁltration rate values other than hyperuricemia.
Again, it is known that CKD can cause elevated serum UA level
per se; thus, it is difﬁcult to say whether CKD is secondary to
hyperuricemia or vice versa. Lastly, the authors did not state the
speciﬁc laboratory method by which they studied serum UA
level. They used cutoff values primarily based on the literature,
which we think are inappropriate, because we do not know
their laboratory cutoff for hyperuricemia.
To reach a decision that might affect the lifestyle of many
people, the authors might have controlled for most, if not all,
of the confounding variables that affect UA level other than
sugar-sweetened soda.
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The Authors Reply: We agree with the comments by Solak
et al.1 on the importance of adjusting, if possible, for
medications and co-morbid conditions that can affect uric acid
and creatinine levels. Indeed, we identify this limitation
ourselves in the discussion of our results2 and acknowledge
that the lack of such detailed information is an inherent
shortcoming of any observational analysis. Thus, we are
empowered to speak only of associations rather than causation.
We disagree with their comments about deﬁnitions
used for chronic kidney disease (CKD) and hyperuricemia.
As stated in the discussion and published online in
supplementary tables, we used alternative deﬁnitions of
CKD based on changes in serum creatinine, estimated
glomerular ﬁltration rate, and urinary albumin excretion;
the lack of association remained. Sex-speciﬁc cutoff points for
hyperuricemia that are lower than conventional, gender-
neutral cutoff points allow for a more sensitive deﬁnition of
hyperuricemia and should theoretically provide a greater
likelihood of detecting an association between exposure and
outcome. In addition, supplementary analyses treating uric
acid outcomes as a continuous variable failed to show an
association between sugar-sweetened beverage consumption
and any change in uric acid levels.
Finally, we do not think it is prudent for the associations
drawn from any single epidemiologic analysis, including ours,
‘to affect the lifestyle of many people,’ as Solak et al.1 assert. We
reiterate that our ﬁndings do not justify unrestrained
consumption of sugar-sweetened sodas by individuals with or
without hyperuricemia or CKD. Rather, we intend the results
from our longitudinal analyses in this and other cohorts3
to add new, objective information to the still-growing body of
literature surrounding the potential health consequences of
sugar-sweetened soda.4 We hope that the scrutiny paid to our
‘negative’ study by Solak et al.,1 as well as by Curhan and
Forman5 in their accompanying editorial, is applied equally to
past, present, and future ‘positive’ studies on this subject. We
agree with Curhan and Forman’s ﬁnal suggestion to readers
(and their patients) that sugar-sweetened beverages should be
avoided, but we disagree that the evidence for beneﬁt from such
behavior is ‘overwhelming’ with regard to kidney function.
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Non-infected central venous
catheters in hemodialysis patients
are not associated with
inflammation
To the Editor: A recent study, conducted by Goldstein et al.,
showed that the serum C-reactive protein (CRP) level of
patients who underwent hemodialysis (HD) with non-
infected central venous catheters (CVCs) was higher than
that of those who underwent HD via native arteriovenous
ﬁstulas (AVFs). In these patients, betadine solution was used
for exit-site care.1 Our aim was to evaluate the changes in the
serum CRP levels of HD patients who underwent dialysis via
native AVF (AVF-1), then via temporary tunneled CVC for
AVF dysfunction, and again via AVF (AVF-2). Eighteen
tunneled jugular CVCs in 18 HD patients were included.
Heparin lock and alcoholic-chlorhexidine solution was used
for exit-site disinfection. The mean CRP values during the
three periods were not different (Figure 1). A cross-sectional
study in 225 HD patients in December 2008 showed that
the median serum CRP levels of patients using AVF (89%)
and CVC (11%) were 7 (IQR 3–20) and 10 (3–21)mg/l,
respectively (NS). We have previously shown that the
incidence of catheter-related bacteremia decreased from
1.1 to 0.2/1000 catheter day during 1994–1997 and
2004–2007 when betadine was substituted with alcohol-
chlorhexidine solution.2 As this solution was more efﬁcient
than betadine in our hands, we hypothesized that the
difference in the ﬁndings reported in the two studies may
be attributed to the differences in the solution used. However,
to conﬁrm this hypothesis, a controlled study should be
conducted in order to compare these two protocols.
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The Authors Reply: We thank Dr Jean and colleagues1 for
their interest in our work.2 They question our ﬁndings of
increased C-reactive protein (CRP) using a non-infected
hemodialysis catheter. The ﬁndings of their study contradict
ours, and all previous studies, which reported an increase in
the inﬂammation associated with catheter use compared with
arteriovenous ﬁstulas.3–5 One study4 assessed 128 prevalent
chronic hemodialysis patients (2405 CRP measurements),
ﬁnding catheter presence was independently associated with
CRP level, and catheter placement or removal was associated
with an increase or improvement in CRP level, respectively.
Our study was the ﬁrst to evaluate non-infected catheters as a
sole mechanism for inﬂammation, adjusted for potential
confounding variables. The authors hypothesize the reason
that they did not observe increased CRP in catheter patients
was because of different antiseptic use for exit site care. They
propose a controlled study to directly address the potential for
inﬂammation induction between two protocols. The informa-
tion accumulated in the literature makes such a study
unnecessary and potentially unethical. Even though the
authors’ hypothesis is correct, we are concerned their letter
implies catheter use is acceptable based on their small study.
Our group, and others, believes catheters should be avoided in
dialysis patients. In addition to inﬂammation, the increase
in morbidity and mortality associated with catheters is well
established.2 A recent paper ‘Ethical and Legal Obligation to
Avoid Long-Term Tunneled Catheter Access’ reminds us the
ﬁrst duty of a physician is to do no harm.6 In our opinion the
continued catheter use is harmful.
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Figure 1 |CRP evolution. Changes in serum C-reactive protein
(CRP) levels of patients undergoing dialysis first via arteriovenous
fistula (AVF-1), then via central venous catheter (CVC), and again
via arteriovenous fistula (AVF-2). Median (interquartile range)
values are shown.
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